anastrozole has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Premenopausal patients with breast cancer and more than 10 positive axillary nodes (BC>10) have a poor prognosis: In these patients the best adjuvant therapy (CT) has not yet been established." | 1.42 | Adjuvant Ovarian Suppression, High-dose Chemotherapy and Immunotherapy for Premenopausal Patients with High-risk Breast Cancer. ( Bratta, M; Candeloro, G; D'Orazi, V; Fumagalli, LA; Pasta, V; Rea, S; Recchia, F; Rosselli, M, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Recchia, F | 1 |
| Candeloro, G | 1 |
| Rosselli, M | 1 |
| Bratta, M | 1 |
| Pasta, V | 1 |
| D'Orazi, V | 1 |
| Fumagalli, LA | 1 |
| Rea, S | 1 |
1 other study available for anastrozole and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Adjuvant Ovarian Suppression, High-dose Chemotherapy and Immunotherapy for Premenopausal Patients with High-risk Breast Cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2015 |